Glazer Capital, LLC Coherus Bio Sciences, Inc. Transaction History
Glazer Capital, LLC
- $2.16 Billion
- Q1 2025
A detailed history of Glazer Capital, LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Glazer Capital, LLC holds 1 shares of CHRS stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1Holding current value
$0% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CHRS
# of Institutions
123Shares Held
64.5MCall Options Held
96.6KPut Options Held
65.3K-
Black Rock Inc. New York, NY11.8MShares$8.93 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$8.48 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY5.26MShares$4 Million0.12% of portfolio
-
Tang Capital Management LLC San Diego, CA5.1MShares$3.87 Million0.27% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$2.31 Million0.11% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $59.1M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...